Nuvectis Pharma Reports Director Changes and Officer Compensation Adjustments
Ticker: NVCT · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1875558
| Field | Detail |
|---|---|
| Company | Nuvectis Pharma, Inc. (NVCT) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, officer-compensation, corporate-governance
TL;DR
Nuvectis Pharma shakes up board, adjusts exec pay. Keep an eye on strategy shifts.
AI Summary
Nuvectis Pharma, Inc. filed an 8-K on September 25, 2025, reporting on the departure of a director, election of a new director, and changes in officer compensation. The filing also includes financial statements and exhibits. The earliest event reported was on September 22, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directorship and officer compensation can indicate internal shifts that may affect company direction and performance.
Key Players & Entities
- Nuvectis Pharma, Inc. (company) — Registrant
- September 22, 2025 (date) — Earliest event reported
- September 25, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Fort Lee, NJ (location) — Principal executive offices
FAQ
Who departed from the board of directors at Nuvectis Pharma?
The filing indicates the departure of a director, but the specific name is not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 22, 2025.
What is the principal executive office address for Nuvectis Pharma?
The principal executive offices are located at 1 Bridge Plaza, Suite 275, Fort Lee, NJ 07024.
What is the SIC code for Nuvectis Pharma?
The Standard Industrial Classification (SIC) code for Nuvectis Pharma is 2834, Pharmaceutical Preparations.
What items are covered in this 8-K filing?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and financial statements and exhibits.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-25 08:23:11
Filing Documents
- tm2526892d1_8k.htm (8-K) — 24KB
- tm2526892d1_ex99-1.htm (EX-99.1) — 12KB
- tm2526892d1_ex99-1img01.jpg (GRAPHIC) — 5KB
- 0001104659-25-093144.txt ( ) — 208KB
- nvct-20250922.xsd (EX-101.SCH) — 3KB
- nvct-20250922_lab.xml (EX-101.LAB) — 33KB
- nvct-20250922_pre.xml (EX-101.PRE) — 22KB
- tm2526892d1_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 22, 2025, the Board of Directors (the "Board") of Nuvectis Pharma, Inc. (the "Company") appointed Juan Sanchez, MD, to the Board. Dr. Sanchez will serve as a director until his term expires at the 2026 annual meeting of stockholders, at which time he will stand for election by the Company's stockholders. Dr. Sanchez has (i) no arrangements or understandings with any other person pursuant to which he was appointed to as a director, and (ii) no family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer. Dr. Sanchez has no direct or indirect material interest in any transaction or series of similar transactions contemplated by Item 404(a) of Regulation S-K. The Company announced Dr. Sanchez's appointment via press release on September 25, 2025. A copy of the press release is being filed as Exhibit 99.1 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished herewith: Exhibit Number Description 99.1 Press release issued by Nuvectis Pharma, Inc., dated September 25, 2025. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvectis Pharma, Inc. (Registrant) Date: September 25, 2025 By: /s/ Ron Bentsur Ron Bentsur Chairman, Chief Executive Officer and President